207 related articles for article (PubMed ID: 10210327)
1. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.
London CA; Galli SJ; Yuuki T; Hu ZQ; Helfand SC; Geissler EN
Exp Hematol; 1999 Apr; 27(4):689-97. PubMed ID: 10210327
[TBL] [Abstract][Full Text] [Related]
2. Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs.
Zavodovskaya R; Chien MB; London CA
J Vet Intern Med; 2004; 18(6):915-7. PubMed ID: 15638281
[TBL] [Abstract][Full Text] [Related]
3. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.
Ma Y; Longley BJ; Wang X; Blount JL; Langley K; Caughey GH
J Invest Dermatol; 1999 Feb; 112(2):165-70. PubMed ID: 9989791
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs.
Downing S; Chien MB; Kass PH; Moore PE; London CA
Am J Vet Res; 2002 Dec; 63(12):1718-23. PubMed ID: 12492288
[TBL] [Abstract][Full Text] [Related]
6. Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline.
Marconato L; Zorzan E; Giantin M; Di Palma S; Cancedda S; Dacasto M
J Vet Intern Med; 2014; 28(2):547-53. PubMed ID: 24372836
[TBL] [Abstract][Full Text] [Related]
7. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.
Tsujimura T; Morimoto M; Hashimoto K; Moriyama Y; Kitayama H; Matsuzawa Y; Kitamura Y; Kanakura Y
Blood; 1996 Jan; 87(1):273-83. PubMed ID: 8547652
[TBL] [Abstract][Full Text] [Related]
9. Canine mast cell tumors express stem cell factor receptor.
Reguera MJ; Rabanal RM; Puigdemont A; Ferrer L
Am J Dermatopathol; 2000 Feb; 22(1):49-54. PubMed ID: 10698217
[TBL] [Abstract][Full Text] [Related]
10. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
11. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.
Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA
Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs.
Zemke D; Yamini B; Yuzbasiyan-Gurkan V
Vet Pathol; 2002 Sep; 39(5):529-35. PubMed ID: 12243462
[TBL] [Abstract][Full Text] [Related]
13. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
14. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3.
Tsujimura T; Furitsu T; Morimoto M; Kanayama Y; Nomura S; Matsuzawa Y; Kitamura Y; Kanakura Y
Int Arch Allergy Immunol; 1995 Apr; 106(4):377-85. PubMed ID: 7536501
[TBL] [Abstract][Full Text] [Related]
15. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation.
Tsujimura T; Furitsu T; Morimoto M; Isozaki K; Nomura S; Matsuzawa Y; Kitamura Y; Kanakura Y
Blood; 1994 May; 83(9):2619-26. PubMed ID: 7513208
[TBL] [Abstract][Full Text] [Related]
16. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
17. Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats.
Dank G; Chien MB; London CA
Am J Vet Res; 2002 Aug; 63(8):1129-33. PubMed ID: 12171166
[TBL] [Abstract][Full Text] [Related]
18. Characterization of an undifferentiated malignancy as a mast cell tumor using mutation analysis in the proto-oncogene c-KIT.
Zemke D; Yamini B; Yuzbasiyan-Gurkan V
J Vet Diagn Invest; 2001 Jul; 13(4):341-5. PubMed ID: 11478608
[TBL] [Abstract][Full Text] [Related]
19. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
[TBL] [Abstract][Full Text] [Related]
20. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
